相关实验视频

Updated: May 1, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

对VMAT对Halcyon和Infinity的计划进行比较分析,用于肺癌放射治疗

Kainan Shao¹, Fenglei Du², Lingyun Qiu¹

¹Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, HangZhou, Zhejiang, China.

|February 11, 2025

概括

这项研究比较了Halcyon和Infinity线性加速器用于非小细胞肺癌放射治疗. 哈尔基昂提供更好的正常组织节省,而无限提供优越的高剂量控制和效率,与PTV体积影响结果.

科学领域:

辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

对于NSCLC治疗,VMAT规划至关重要.
对比线性加速器平台 (Halcyon,Infinity) 对于临床设备的选择至关重要.

研究的目的:

为了比较NSCLC的Halcyon和Infinity平台上的VMAT计划的剂量测量特性和处理效率.
确定影响治疗结果的混因素.

主要方法:

60名NSCLC患者的回顾性队列研究.
在Halcyon和Infinity上使用RayStation 9A优化了VMAT计划.
目标覆盖率,正常组织节省,计划复杂性和治疗效率的比较.
对混因素 (PTV体积,瘤阶段,位置) 的后勤回归分析.

主要成果:

这两种平台都符合临床剂量测量要求.
哈尔基昂证明了优越的低剂量节省肺和心脏.
无限在高剂量控制和快速剂量下降方面表现出色.
在Halcyon计划中,MU较少,复杂性较低,治疗时间减少了24%.
PTV体积是剂量指标差异的重要预测指标.

结论:

哈尔基昂和无限为NSCLC放射治疗提供了明显的优势.
哈尔基昂在节省正常组织方面表现出色;无限在高剂量控制和效率方面.
PTV体积是影响剂量测量结果的关键因素.
推个性化治疗计划,利用独特的加速器特性.

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...